» Authors » Jimmy Light

Jimmy Light

Explore the profile of Jimmy Light including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 9
Citations 337
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Light J, Tucker M
Clin Transplant . 2013 Mar; 27(3):E256-63. PMID: 23480129
Introduction: We are reporting the results over a 20 yr period of simultaneous pancreas-kidney transplants in patients with end-stage renal disease and diabetes mellitus. The outcomes of the transplants, performed...
2.
Harbell J, Fung J, Nissen N, Olthoff K, Florman S, Hanto D, et al.
Surgery . 2012 Sep; 152(3):376-81. PMID: 22938898
Background: In this report, we examine the surgical safety and complications (SC) among 125 liver (L) and 150 kidney (K) HIV+ transplantation (TX) recipients in a prospective nonrandomized U.S. multicenter...
3.
Melancon J, Cummings L, Graham J, Rosen-Bronson S, Light J, Desai C, et al.
J Am Coll Surg . 2011 Apr; 212(4):740-5. PMID: 21463825
Background: Currently ethnic minority patients comprise 60% of patients listed for kidney transplantation in the US; however, they receive only 55% of deceased donor renal transplants and 25% of living...
4.
Orlando G, Stratta R, Light J
Curr Opin Organ Transplant . 2010 Dec; 16(1):110-5. PMID: 21150617
Purpose Of Review: This review will provide evidence that selected patients with type 2 diabetes mellitus (T2DM) may benefit from vascularized pancreas transplantation (PTX). Recent Findings: Initial experience with simultaneous...
5.
Stock P, Barin B, Murphy B, Hanto D, Diego J, Light J, et al.
N Engl J Med . 2010 Nov; 363(21):2004-14. PMID: 21083386
Background: The outcomes of kidney transplantation and immunosuppression in people infected with human immunodeficiency virus (HIV) are incompletely understood. Methods: We undertook a prospective, nonrandomized trial of kidney transplantation in...
6.
Vincenti F, Mendez R, Curtis J, Light J, Pearson T, Wu Y, et al.
Transplantation . 2005 Oct; 80(7):910-6. PMID: 16249738
Background: Monitoring cyclosporine microemulsion (CsA-ME; Neoral) exposure 2 hours postdose (C2) has been reported to optimize the efficacy and safety of CsA-ME therapy. The addition of induction therapy to a...
7.
Jordan S, Tyan D, Stablein D, McIntosh M, Rose S, Vo A, et al.
J Am Soc Nephrol . 2004 Dec; 15(12):3256-62. PMID: 15579530
Reported are the reduction of anti-HLA antibody levels and improvement of transplant rates by intravenous immunoglobulin (IVIG) in a randomized, double-blind, placebo-controlled clinical trial. Between 1997 and 2000, a total...
8.
Gonwa T, Johnson C, Ahsan N, Alfrey E, Halloran P, Stegall M, et al.
Transplantation . 2003 Jun; 75(12):2048-53. PMID: 12829910
Methods: Two hundred twenty-three recipients of first cadaveric kidney allografts were randomized to receive tacrolimus (TAC) + mycophenolate mofetil (MMF), TAC + azathioprine (AZA), or cyclosporine (Neoral; CsA) + MMF....
9.
Light J, Salomon D, Diethelm A, Alexander J, Hunsicker L, Thistlethwaite R, et al.
Clin Transplant . 2002 Sep; 16(5):317-24. PMID: 12225426
Background: The safety and immune tolerance potential of donor marrow infusion with cadaveric source renal transplants was evaluated in a series of non-randomized multicenter pilot trials by the NIH Cooperative...